JAZZ:NASDAQ
Jazz Pharmaceuticals PLC
218,42 $
arrow_downward
−1,81%(−4,03) 1D
218,42 $
0,00% (0,00)
bedtimePo zaprtju
Zaprto: 9. okt., 16:00:01 GMT -4 · USD
search
Vsi simboli
| Simbol | Cena | Sprememba | Odstotna sprememba |
|---|
insights_autoGeneriranje najpomembnejših vpogledov za JAZZ …
Odpri
221,79 $
Visoka
227,00 $
Nizka
213,20 $
Tržna kapitalizacija
14,18 mrd.
Povprečni promet
935,53 tis.
Promet
1,29 mio.
Razmerje med ceno delnice in čistim dobičkom
14,93
52-tedenski najvišji tečaj
266,38 $
52-tedenski najnižji tečaj
128,80 $
Čisti dobiček na delnico
14,63 $
Beta
0,37
Št. izdanih delnic
64,92 mio.
Št. zaposlenih
3 tis.
Odpri
221,79 $
Visoka
227,00 $
Nizka
213,20 $
Tržna kapitalizacija
14,18 mrd.
Povprečni promet
935,53 tis.
Promet
1,29 mio.
Razmerje med ceno delnice in čistim dobičkom
14,93
52-tedenski najvišji tečaj
266,38 $
52-tedenski najnižji tečaj
128,80 $
Čisti dobiček na delnico
14,63 $
Beta
0,37
Št. izdanih delnic
64,92 mio.
Št. zaposlenih
3 tis.
Novice
Iz spletnih virov in novičarskih partnerjev
Traders Union
·
pred 15 urami
Jazz Pharmaceuticals gets Cramer backing in CNBC stock call segment
TipRanks
·
pred 1 dnevom
Jazz Pharmaceuticals Plans Commercial Leadership Transition Ahead
ChartMill
·
pred 1 dnevom
Jazz Pharmaceuticals (NASDAQ:JAZZ): An Undervalued Biopharma Value Stock
AD HOC NEWS
·
pred 2 dnevoma
Truist raises target for Jazz Pharmaceuticals stock to USD 286.00
Profil
Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Vizitka: Jazz Pharmaceuticals PLC
Generalni direktorBruce C Cozadd
Št. zaposlenih2,89 tis.
Ustanovljeno2003
Sedež-
Sektor-
Spletno mestojazzpharma.com